Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss

J. L. Roberts, V. Fiedler, J. Imperato-McGinley, D. Whiting, E. Olsen, J. Shupack, D. Stough, R. DeVillez, R. Rietschel, R. Savin, W. Bergfeld, J. Swinehart, T. Funicella, M. Hordinsky, N. Lowe, I. Katz, A. Lucky, L. Drake, V. H. Price, D. WeissE. Whitmore, L. Millikan, S. Muller, C. Gencheff, P. Carrington, B. Binkowitz, P. Kotey, W. He, K. Bruno, C. Jacobsen, L. Terranella, G. J. Gormley, K. D. Kaufman

Research output: Contribution to journalArticlepeer-review

87 Scopus citations

Abstract

Background: Androgenetic alopecia is a common condition of adult men. Finasteride, a type 2 5α-reductase inhibitor, decreases the formation of dihydrotestosterone from testosterone. Objective: Two separate clinical studies were conducted to establish the optimal dose of finasteride in men with this condition. Methods: Men from 18 to 36 years of age with moderate vertex male pattern hair loss received finasteride 5, 1, 0.2, or 0.01 mg/day or placebo based on random assignment. Efficacy was determined by scalp hair counts, patient self-assessment, investigator assessment, and assessment of clinical photographs. Safety was assessed by clinical and laboratory measurements and by analysis of adverse experiences. Results: Efficacy was demonstrated for all end points for finasteride at doses of 0.2 mg/day or higher, with 1 and 5 mg demonstrating similar efficacy that was superior to lower doses. Efficacy of the 0.01 mg dose was similar to placebo. No significant safety issues were identified in the trials. Conclusion: Finasteride 1 mg/day is the optimal dose for the treatment of men with male pattern hair loss and was subsequently identified for further clinical development.

Original languageEnglish (US)
Pages (from-to)555-563
Number of pages9
JournalJournal of the American Academy of Dermatology
Volume41
Issue number4
DOIs
StatePublished - 1999

Fingerprint

Dive into the research topics of 'Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss'. Together they form a unique fingerprint.

Cite this